Aker BioMarine sees strong Q3 2025 growth driven by human health ingredients

Aker BioMarine announced a 15% year-over-year revenue increase to $56.8m in Q3 2025, with adjusted EBITDA climbing 50% to $12.2m. The Human Health Ingredients (HHI) segment was a key driver, seeing revenues rise 23% to $30.2m and adjusted EBITDA grow 35% to $13.5m, supported by strong demand and a new supply agreement for Superba Krill Oil. The company also highlighted improved gross margins for HHI and stable EBITDA margins for Consumer Health Products, despite a 6% revenue decline in the latter to $27.4m.

Emerging Business revenues remained stable at $2.0m, with EBITDA improving due to reduced operational expenses. The company is actively pursuing transactions to bring this segment to cash break-even. Overall, Aker BioMarine's strategic focus on science-backed nutraceutical ingredients, including its krill oil and new product portfolio, positions it in attractive segments of the growing Omega-3 market.

The company's outlook anticipates continued growth for HHI, modest market growth for Consumer Health Products, and a leaner cost base at the corporate level, with established underlying costs of $12-14m. Initiatives are underway to enhance financial and operational efficiency, while assessing macroeconomic uncertainties and potential tariff impacts.